{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:34Z","timestamp":1792788994786,"version":"4.5.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Invasive meningococcal disease (IMD) is life-threatening and associated with substantial morbidity and mortality. The study aimed to examine the clinical characteristics and hospital-based healthcare resource use and related costs following IMD diagnosis in France.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients admitted to hospitals due to IMD between 2014 and 2016 were selected from the French hospital discharge database (PMSI). Demographics, clinical outcomes and health utilization (HRU) during index hospitalization were described. HRU and costs during the follow-up period were also examined. A generalized linear model was applied to examine 1-year costs after index hospitalization adjusting for age, type of IMD and presence of sequelae at index hospitalization.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 1,344 patients were identified. About 30% cases were in children &lt; 5 years old and 25% aged 10\u201324 years. Majority of patients presented as meningococcal meningitis (59%), 25% as meningococcaemia, and 9% both. The case fatality rate during the index hospitalization was 6%. About 15% of patients had at least one sequela at index hospital discharge. The median length of stay and the median cost of index hospitalization were 9 days and 8,045\u20ac, respectively. Patients with at least one sequela, with clinical manifestation as both meningitis and meningococcaemia, or aged 25 years and older were statistically significantly associated with higher costs than others.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>IMD is unpredictable and can occur in all ages. The study highlights the severity and high health and economic burdens associated with the disease. The data underlines the importance of prevention against IMD through vaccination.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0267786","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:31:46Z","timestamp":1651253506000},"page":"e0267786","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["A database study of clinical and economic burden of invasive meningococcal disease in France"],"prefix":"10.1371","volume":"17","author":[{"given":"Liping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fievez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Goguillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-2488","authenticated-orcid":true,"given":"Lucile","family":"Mari\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e8ve","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Elka\u00efm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myint","family":"Tin Tin Htar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"pone.0267786.ref001","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis","volume":"134","author":"A Purmohamad","year":"2019","journal-title":"Microb Pathog"},{"issue":"2 Suppl","key":"pone.0267786.ref002","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements","volume":"59","author":"F. Martin\u00f3n-Torres","year":"2016","journal-title":"J Adolesc Health Off Publ Soc Adolesc Med"},{"issue":"4","key":"pone.0267786.ref003","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers","volume":"7","author":"KJ Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"7","key":"pone.0267786.ref004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","article-title":"The clinical features and long-term sequelae of invasive meningococcal disease in children","volume":"33","author":"C Stein-Zamir","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"pone.0267786.ref005","first-page":"1","article-title":"Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries","author":"MK Taha","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"pone.0267786.ref006","unstructured":"Mathers CD, Bernard C, Moesgaard Iburg K, Inoue M, Ma Fat D, Shibuya K, et al. Global Burden of Disease in 2002: data sources, methods and results. [Internet]. World Health Organization; 2003 d\u00e9c. Disponible sur: https:\/\/www.who.int\/healthinfo\/paper54.pdf"},{"key":"pone.0267786.ref007","unstructured":"S\u00e9rie 001765611 Indice annuel des prix \u00e0 la consommation\u2014Base 2015\u2014Ensemble des m\u00e9nages\u2014France m\u00e9tropolitaine\u2014Services de sant\u00e9| Insee [Internet]. [cit\u00e9 23 avr 2019]. Disponible sur: https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001765611"},{"key":"pone.0267786.ref008","unstructured":"Les infections invasives \u00e0 m\u00e9ningocoque en France en 2016 [Internet]. Sant\u00e9 publique France; 2016 d\u00e9c [cit\u00e9 26 juin 2020]. Disponible sur: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/donnees\/les-infections-invasives-a-meningocoque-en-france-en-2016"},{"key":"pone.0267786.ref009","unstructured":"Les infections invasives \u00e0 m\u00e9ningocoque en France en 2015 [Internet]. Sant\u00e9 publique France; 2015 d\u00e9c [cit\u00e9 26 juin 2020]. Disponible sur: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/donnees\/les-infections-invasives-a-meningocoque-en-france-en-2015"},{"key":"pone.0267786.ref010","unstructured":"Les infections invasives \u00e0 m\u00e9ningocoque en France en 2014 [Internet]. Sant\u00e9 publique France; 2014 d\u00e9c [cit\u00e9 26 juin 2020]. Disponible sur: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/donnees\/les-infections-invasives-a-meningocoque-en-france-en-2014"},{"key":"pone.0267786.ref011","unstructured":"Surveillance Atlas of Infectious Diseases [Internet]. [cit\u00e9 26 juin 2020]. Disponible sur: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx"},{"issue":"4","key":"pone.0267786.ref012","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1542\/peds.2006-0281","article-title":"Multicenter surveillance of invasive meningococcal infections in children","volume":"118","author":"SL Kaplan","year":"2006","journal-title":"Pediatrics"},{"issue":"21","key":"pone.0267786.ref013","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"B Wang","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"pone.0267786.ref014","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis","volume":"10","author":"K Edmond","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pone.0267786.ref015","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpedi.162.11.1036","article-title":"Long-term health status in childhood survivors of meningococcal septic shock","volume":"162","author":"CMP Buysse","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"pone.0267786.ref016","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","article-title":"Costs of Invasive Meningococcal Disease: A Global Systematic Review","volume":"36","author":"B Wang","year":"2018","journal-title":"PharmacoEconomics"},{"key":"pone.0267786.ref017","unstructured":"Conversion rates\u2014Purchasing power parities (PPP)\u2014OECD Data [Internet]. theOECD. [cit\u00e9 26 juin 2020]. Disponible sur: http:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm"},{"key":"pone.0267786.ref018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CEOR.S175835","article-title":"Societal costs due to meningococcal disease: a national registry-based study","volume":"Volume 10","author":"N Gustafsson","year":"2018","journal-title":"Clin Outcomes Res"},{"issue":"4","key":"pone.0267786.ref019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/hv.7.4.14434","article-title":"Cost impact of complications in meningococcal disease: evidence from a United States managed care population","volume":"7","author":"KL Davis","year":"2011","journal-title":"Hum Vaccin. avr"},{"issue":"4","key":"pone.0267786.ref020","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.ehrm.2011.08.001","article-title":"Costs of Sequelae Associated with Invasive Meningococcal Disease: Findings from a US Managed Care Population","volume":"2","author":"S Karve","year":"2011","journal-title":"Health Outcomes Res Med"},{"issue":"37","key":"pone.0267786.ref021","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"B Wang","year":"2014","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:32:07Z","timestamp":1651253527000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267786"}},"subtitle":[],"editor":[{"given":"Carla","family":"Pegoraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267786","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}